Janux Therapeutics, Inc.
JANX
$23.80
$0.532.28%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.12% | 30.99% | 54.12% | 94.86% | -19.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.12% | 30.99% | 54.12% | 94.86% | -19.67% |
| Cost of Revenue | 49.40% | 24.52% | 2.94% | -11.44% | -10.14% |
| Gross Profit | -52.79% | -23.40% | 5.79% | 27.25% | 8.41% |
| SG&A Expenses | 61.17% | 57.03% | 53.92% | 11.30% | 13.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.37% | 35.00% | 18.47% | -4.72% | -3.32% |
| Operating Income | -55.89% | -35.45% | -14.45% | 14.72% | 1.32% |
| Income Before Tax | -39.84% | -18.36% | 3.30% | 34.97% | 17.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.84% | -18.36% | 3.30% | 34.97% | 17.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.84% | -18.36% | 3.30% | 34.97% | 17.16% |
| EBIT | -55.89% | -35.45% | -14.45% | 14.72% | 1.32% |
| EBITDA | -57.48% | -36.27% | -14.47% | 15.68% | 2.47% |
| EPS Basic | -11.00% | 4.61% | 20.33% | 43.67% | 24.13% |
| Normalized Basic EPS | -11.00% | 4.62% | 20.34% | 43.67% | 24.14% |
| EPS Diluted | -11.00% | 4.61% | 20.33% | 43.67% | 24.13% |
| Normalized Diluted EPS | -11.00% | 4.62% | 20.34% | 43.67% | 24.14% |
| Average Basic Shares Outstanding | 24.24% | 22.14% | 19.85% | 17.50% | 10.19% |
| Average Diluted Shares Outstanding | 24.24% | 22.14% | 19.85% | 17.50% | 10.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |